Tumor Ablation Market Set to Surge to US$ 1.8 Billion by 2031, Growing at 11.6% CAGR: Wissen Research

Wissen Research estimates the global tumor ablation market at USD 1.04 billion in 2026 and projects it will reach USD 1.8 billion by 2031, a 11.6% CAGR. Growth is linked to rising cancer patient numbers, minimally invasive treatment demand, and advances in image-guided systems; radiofrequency ablation led by technology in 2025, while Asia Pacific is the fastest-growing region. Adoption remains constrained by procedural challenges near vital structures and the need for clinical evidence, training, and regulatory approval for newer techniques.

Analysis

The market-growth forecast is not itself a trade catalyst: it is a vendor-sponsored estimate, and aggregate category growth may not translate into material earnings for diversified device companies. The more investable mechanism is whether reimbursement and clinical evidence convert selected procedures into repeatable utilization. For AngioDynamics (ANGO), Medicare coverage for specified NanoKnife cases reduces one access barrier, but does not establish broad coverage or commercial scale; procedure volumes, physician adoption, and product revenue contribution remain the key checks. IceCure (ICCM) has a separate, earlier-stage path: Dutch distribution expands reach, while the Phase III THERMAC trial is a potentially more consequential evidence catalyst. Neither item proves durable demand yet.

Competitive advantage may accrue to integrated workflows—imaging, navigation, planning, and monitoring—not simply the energy generator. That could benefit established imaging vendors such as Siemens Healthineers (SHL) if ablation drives incremental system utilization or upgrades, but this article provides no evidence of incremental orders. For diversified peers including MDT, BSX, and JNJ, category growth is likely too small to underwrite a thesis without segment-level exposure data. Thermal modalities also face a practical ceiling near sensitive structures; non-thermal IRE may address some cases, but clinical evidence and eligible indications constrain substitution.

Near term, expect limited read-through from this market report. Over 1–3 months, watch ANGO procedure/revenue commentary and ICCM trial or channel updates. Over 6–18 months, adoption depends on reproducible outcomes, reimbursement breadth, and training capacity. The contrarian point: the forecast emphasizes patient need and technology breadth, while investors should focus on procedure economics and evidence; adoption can lag market growth materially.

Key Decisions for Investors

• No broad sector position based on the forecast. Treat it as a market-sizing claim, not an earnings revision; avoid extrapolating category growth to MDT, BSX, JNJ, or SHL without segment-level exposure and order evidence.
• Put ANGO on a catalyst watch rather than buying solely on the coverage announcement. Reassess if company disclosures show sustained growth in eligible NanoKnife procedures and associated revenue; thesis weakens if utilization or guidance fails to respond despite coverage.
• Keep ICCM as a higher-risk clinical-commercial watch item, not a confirmed distribution-led growth trade. Track THERMAC Phase III milestones, Dutch reorder activity, and evidence of broader adoption; trial setbacks or weak channel conversion would invalidate the upside case.
• For a possible workflow angle, monitor SHL and other imaging suppliers for ablation-linked upgrades or utilization, but do not initiate a trade without company-level evidence that this niche is driving incremental sales.